Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II.
Robert Glynne-Jones
Research Funding - Roche
Roger James
No relevant relationships to disclose
Helen Meadows
No relevant relationships to disclose
Rubina Begum
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Amgen (U); Roche (U)
Research Funding - Amgen; AstraZeneca; Roche
Expert Testimony - Amgen (U); Roche (U)
John Northover
No relevant relationships to disclose
Jonathan A. Ledermann
No relevant relationships to disclose
Sandra Beare
No relevant relationships to disclose
Latha Kadalayil
No relevant relationships to disclose
David Sebag-Montefiore
No relevant relationships to disclose